IPG7236

In vivo efficacy studies were conducted using the EMT6 syngeneic breast tumor model, characterized by an immunosuppressive tumor microenvironment, assessing the antitumor effects of a CCR8-targeted small molecule (IPG7236) as monotherapy or in combination with anti-PD-L1 treatment...This study identifies Treg-enriched and immunosuppressive breast cancer subtype through integrative multi-omics analysis and demonstrates, through both in-silico and in-vivo approaches, the therapeutic potential of combining Treg-targeted and PD-L1 blockade therapies. These findings highlight Treg-mediated immunosuppression as a key determinant of therapeutic responsiveness, providing a biological rationale for patient stratification and guiding the development of personalized combination strategies for clinical translation.

P1, N=63, Terminated, Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Nov 2022 --> Nov 2025 | Not yet recruiting --> Terminated; Sponsor decision

P1/2, N=196, Recruiting, Nanjing Immunophage Biotech Co., Ltd | Phase classification: P1 --> P1/2

P1, N=196, Recruiting, Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Sep 2025

P1, N=196, Recruiting, Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

IPG7236 alone or in combination with PD-1 antibody exhibited significant tumor suppression effects in the mouse xenograft model of human breast cancer. IPG7236 is a promising clinical candidate that targets CCR8 with excellent in vitro ADMET properties, pharmacokinetics, safety profiles, and in vivo efficacy.